NasdaqGS - Delayed Quote USD

NovoCure Limited (NVCR)

Compare
26.33
+26.33
(-2.55%)
At close: January 24 at 4:00:00 PM EST
26.04
-0.29
(-1.10%)
After hours: January 24 at 5:09:08 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
577,738.00
509,338.00
537,840.00
535,031.00
494,366.00
Cost of Revenue
136,271.00
128,280.00
114,867.00
114,877.00
106,501.00
Gross Profit
441,467.00
381,058.00
422,973.00
420,154.00
387,865.00
Operating Expense
600,375.00
613,928.00
512,496.00
464,487.00
357,464.00
Operating Income
-158,908.00
-232,870.00
-89,523.00
-44,333.00
30,401.00
Net Non Operating Interest Income Expense
45,215.00
41,927.00
11,200.00
-3,710.00
-14,947.00
Other Income Expense
--
-797.00
-3,523.00
-4,032.00
2,648.00
Pretax Income
-114,490.00
-191,740.00
-81,846.00
-52,075.00
18,102.00
Tax Provision
35,294.00
15,303.00
10,688.00
6,276.00
-1,706.00
Net Income Common Stockholders
-149,784.00
-207,043.00
-92,534.00
-58,351.00
19,808.00
Diluted NI Available to Com Stockholders
-149,784.00
-207,043.00
-92,534.00
-58,351.00
19,808.00
Basic EPS
-1.39
-1.95
-0.88
-0.56
0.20
Diluted EPS
-1.39
-1.95
-0.88
-0.56
0.18
Basic Average Shares
107,486.41
106,391.18
104,660.48
103,433.27
100,930.87
Diluted Average Shares
107,486.41
106,391.18
104,660.48
103,433.27
108,877.65
Total Operating Income as Reported
-158,908.00
-232,870.00
-89,523.00
-44,333.00
30,401.00
Total Expenses
736,646.00
742,208.00
627,363.00
579,364.00
463,965.00
Net Income from Continuing & Discontinued Operation
-149,784.00
-207,043.00
-92,534.00
-58,351.00
19,808.00
Normalized Income
-149,154.37
-206,413.37
-89,750.83
-55,407.64
17,874.96
Interest Income
--
19,639.00
10,961.00
791.00
1,787.00
Interest Expense
--
3,319.00
3,334.00
3,440.00
17,582.00
Net Interest Income
45,215.00
41,927.00
11,200.00
-3,710.00
-14,947.00
EBIT
-114,459.00
-188,421.00
-78,512.00
-48,635.00
35,684.00
EBITDA
-103,605.00
-177,452.00
-67,888.00
-38,384.00
44,834.00
Reconciled Cost of Revenue
136,271.00
128,280.00
114,867.00
114,877.00
106,501.00
Reconciled Depreciation
10,854.00
10,969.00
10,624.00
10,251.00
9,150.00
Net Income from Continuing Operation Net Minority Interest
-149,784.00
-207,043.00
-92,534.00
-58,351.00
19,808.00
Total Unusual Items Excluding Goodwill
-797.00
-797.00
-3,523.00
-4,032.00
2,648.00
Total Unusual Items
-797.00
-797.00
-3,523.00
-4,032.00
2,648.00
Normalized EBITDA
-102,808.00
-176,655.00
-64,365.00
-34,352.00
42,186.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-167.37
-167.37
-739.83
-1,088.64
714.96
12/31/2020 - 10/1/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

QDEL QuidelOrtho Corporation
44.24
-0.20%
 
NARI Inari Medical, Inc.
79.74
+0.35%
 
INSP Inspire Medical Systems, Inc.
188.47
+0.47%
 
EW Edwards Lifesciences Corporation
68.99
+0.09%
 
SNN Smith & Nephew plc
25.08
+0.36%
 
BRKR Bruker Corporation
57.29
-1.55%
 
DXCM DexCom, Inc.
88.75
+1.20%
 
IART Integra LifeSciences Holdings Corporation
26.05
+1.76%
 
GKOS Glaukos Corporation
160.22
-0.62%
 
INGN Inogen, Inc.
11.44
+3.25%